The primary biliary cholangitis treatment market is growing due to increased adoption of ursodeoxycholic acid (UDCA), obeticholic acid, and emerging therapies targeting liver fibrosis and autoimmune pathways. https://www.datamintelligence.com/research-report/primary-biliary-cholangitis-treatment-market